{"hq_id":"hq-c-mix-000085","name":"Coccidioides immitis (Valley Fever)","context":"human_adult","risk_level":"high","schema":"legacy","note":"Synthesis unavailable: compound lacks vectorizable regulatory classifications. Raw safety data returned.","data":{"risk_level":"high","summary":"Coccidioides immitis and C. posadasii are dimorphic soil fungi causing coccidioidomycosis (Valley Fever), an endemic mycosis of the arid and semi-arid American Southwest, Central Valley of California, and Mexico. Infection occurs by inhalation of arthroconidia (barrel-shaped, 2-5 um) from disturbed soil — dust storms, construction, earthquakes, and agricultural work are major risk factors. Estimated 150,000 infections per year in the US; ~60% are asymptomatic. Symptomatic pulmonary coccidioidomycosis causes fever, cough, chest pain, fatigue, and arthralgias ('desert rheumatism'). Disseminated disease (1% of infections) can involve skin, bones, joints, and meninges — coccidioidal meningitis is uniformly fatal without lifelong azole therapy. Risk factors for dissemination: African American and Filipino ancestry (10-175x higher risk), pregnancy (third trimester), immunosuppression, diabetes. Climate change is expanding the endemic range northward — cases now reported in Washington state. Arthroconidia are classified as BSL-3 agents due to extreme infectivity. WHO 2022 Fungal Priority Pathogens: High priority. No approved vaccine, though a Delta-CPS1 vaccine candidate is in clinical development.","source_refs":["aletheia_fungi_batch_2026"]},"meta":{"synthesis_version":"n/a","timestamp":"2026-05-01T14:18:19.077Z"}}